Derived From Animal Tissue (e.g., Rennin, Etc.) Patents (Class 435/226)
  • Protein and nucleic acid sequence encoding a KRILL-derived cold adapted trypsin-like activity enzyme
    Patent number: 7202074
    Abstract: The present invention provides nucleic acid and corresponding amino acid sequences of two isoforms of cold adapted trypsin-like activity protein, insolated from antarctic marine origin, preferably from antarctic krill (Euphausia superba) that can be used in a variety of industrial contexts and commercial purposes including laundry detergents, food processing, drugs and skin care products. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the cold adapted trypsin-like protein.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: April 10, 2007
    Assignee: University of Chile
    Inventors: Juan A. Asenjo, Barbara A. Andrews, Fernando Reyes, Mauricio Salamanca, Luis Burzio
  • Methods of preventing or treating brain ischemia or brain injury
    Patent number: 7202211
    Abstract: The present invention relates to use of Narp inhibitor in order to promote or enhance recovery from ischemic events, particularly focal ischemia of the central nervous system, as well as for preventing or diminishing chronic degenerative changes.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: April 10, 2007
    Assignees: Astellas Pharma Inc., Quark Biotech, Inc.
    Inventors: Alexander Faerman, Sylvia G. Kachalsky, Gregory Hirsch Idelson
  • Human analogs of murine deubiquitinating proteases
    Patent number: 7202073
    Abstract: The present invention is directed to human analogs of murine hematopoetic-specific, cytokine-inducible deubiquinating proteases (“DUBs”) clustered on chromosomes 4 and 8 and their respective regulatory regions. The nucleotides or proteins encoded thereby my be used in assays to identify inhibitors of human DUBs.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: April 10, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Chang Hahn, Hong Liu
  • Antibodies that bind TNF-? converting enzyme
    Patent number: 7199224
    Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: April 3, 2007
    Assignee: Immunex Corporation
    Inventors: Roy A Black, Charles Rauch, Carl J March, Douglas P Cerretti
  • Kallikrein gene
    Patent number: 7199229
    Abstract: The present invention relates to nucleic acid molecules, encoding kallikrein 15, a novel member of the kallikrein family. Also provided herein are vectors and host cells comprising the nucleic acid molecules, and methods for producing kallikrein 15 proteins.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: April 3, 2007
    Assignee: Mount Sinai Hospital
    Inventors: George M. Yousef, Eleftherios P. Diamandis
  • Aggrecanase
    Patent number: 7193073
    Abstract: A novel polypeptide, a polynucleotide encoding this polypeptide, an expression vector comprising this polynucleotide, a cell transfected with the expression vector, an antibody binding to the above polypeptide, a convenient screening method for obtaining an agent for treating joint diseases, and a process for manufacturing a pharmaceutical composition for treating joint diseases are disclosed. The polypeptide is a novel aggrecanase causative of joint diseases (particularly an OA disease).
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: March 20, 2007
    Assignee: Astellas Pharma Inc.
    Inventors: Noboru Yamaji, Kouichi Nishimura, Kunitake Abe
  • Growth regulating proteins
    Patent number: 7192706
    Abstract: The application discloses a new family of proteins, namely the epsin like proteins (ELP). Said proteins comprise an ENTH domain (Epsin NH2 Terminal Homology domain) and have growth inhibiting activity. The disclosed proteins can be used for the diagnosis of hyperproliferative diseases as well as for gene therapy purposes.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: March 20, 2007
    Assignees: Universität Zürich, The Genetics Company, Inc.
    Inventors: Ernst Hafen, Hugo Stocker, Pierre Daram, Benno Shindelholz, Sebastian Breuer
  • Regulation of human caspase-1-like protease
    Patent number: 7192732
    Abstract: Screening methods to identify candidate therapeutic agents using a newly identified human caspases-1-like protease.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: March 20, 2007
    Assignee: Bayer Healthcare AG
    Inventor: Shyam Ramakrishnan
  • Human enzymes of the metalloprotease family
    Patent number: 7189525
    Abstract: This invention relates to newly identified polypeptides which have zinc metalloprotease activities and are referred to as IGS5, and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be stimulators and/or inhibitors which are useful in therapy, and to production of such polypeptides and polynucleotides.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: March 13, 2007
    Assignee: Solvay Pharmaceuticals B.V.
    Inventors: Willy Deleersnijder, Rico Wiegers, Michael Weske
  • Method for refolding enzymes
    Patent number: 7186539
    Abstract: The invention provides methods for efficient recombinant expression, refolding, and purification of Beta-site APP cleaving enzyme (BACE) polypeptides. In various aspects, the method includes the steps of expressing a recombinant construct in bacteria, dissolving inclusion bodies with a denaturant at high pH in the presence of a reducing agent, diluting the solubilized BACE polypeptide in an aqueous solution at a temperature of about 1° C. to 15° C., and incubating the diluted sample at a temperature of about 4° C. to 15° C. until the recombinant BACE polypeptide folds into an active enzyme.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: March 6, 2007
    Assignee: Pharmacia & UpJohn Company
    Inventors: Alfredo Tomasselli, Robert Heinrikson, Donna Paddock, Ana Mildner, Thomas Emmons
  • Polynucleotides encoding novel cysteine proteases of the calpain superfamily, CAN-12v1 and CAN-12v2.
    Patent number: 7186564
    Abstract: The present invention provides novel polynucleotides encoding CAN-12 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of CAN-12 polypeptides, CAN-12v1 and CAN-12v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel CAN-12, CAN-12v1, and CAN-12v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly neuro- and musculo-degenerative conditions. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: March 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jian Chen, Thomas C. Nelson, Roy J. Vaz, Franck Duclos
  • Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
    Patent number: 7179631
    Abstract: Human and murine analogs of DUBs, hematopoietic-specific, cytokine-inducible deubiquitinating proteases, clustered on chromosome 7 and and their respective regulatory regions are identified. The nucleotide or proteins encoded thereby may be used in assays to identify inhibitors of hDUB7, human deubiquitinating enzyme, or mDUB7, mouse deubiquitinating enzyme. The invention also includes transducing peptides comprising an NLS, nuclear localization signal, or transducing sequence of hDUB7 or mDUB7 linked to a cargo molecule, and methods of delivering a biologically active protein, therapeutically effective compound, antisense nucleotide, or test compound to a cell wherein a transducing peptide is added exogenously to a cell.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: February 20, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Chang S. Hahn, Hong Liu
  • Human coagulation factor VII variants
    Patent number: 7176288
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: February 13, 2007
    Assignee: Novo Nordisk HealthCare A/G
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Modified corin molecules having substitute activation sequences and uses thereof
    Patent number: 7176013
    Abstract: This invention relates to novel modified corin molecules, or fragments or derivatives thereof, comprising a substitute activation sequence. The modified corin molecules are cleaved at the substitute activation sequence, thereby generating activated corin molecules, or fragments or derivatives thereof, that exhibit the functional activity of naturally occurring, wild-type corin molecules. The modified corin molecules can be used to treat a variety of diseases or disorders, including congestive heart failure and acute myocardial infarction.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: February 13, 2007
    Assignee: Schering Aktiengesellschaft
    Inventor: Qingyu Wu
  • Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
    Patent number: 7172892
    Abstract: Provided herein are polypeptides designated CVSP14 polypeptides that exhibit protease activity as a single chain or as an activated two chain form. Methods using the polypeptides to identify compounds that modulate the protease activity thereof are provided. The polypeptides also serve as tumor markers.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: February 6, 2007
    Assignee: Dendreon Corporation
    Inventors: Edwin L. Madison, Jiunn-Chern Yeh
  • Ubiquitin-specific protease occurring in the brain and DNA encoding the same
    Patent number: 7157265
    Abstract: A ubiquitin-specific protease occurring in the brain and a DNA encoding it, which are useful for research on the molecular mechanism of the neuroplasticity expression and so on.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: January 2, 2007
    Assignee: Eisai Co., Ltd.
    Inventors: Tatsuo Suzuki, Qing Bao Tian
  • Polypeptide
    Patent number: 7157567
    Abstract: A screening tool and a screening method for a therapeutic agent for type II diabetes, particularly an agent for alleviating insulin resistance are disclosed. A novel polypeptide, a polynucleotide, a vector, a promoter, and a transformant which are useful in the screening tool and the screening method, are also disclosed.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: January 2, 2007
    Assignee: Astellas Pharma, Inc.
    Inventors: Kunitake Abe, Noboru Yamaji, Miyuki Katou, Tetsuo Matsui
  • Serine protease genes related to DPPIV
    Patent number: 7157241
    Abstract: Novel proteins or polypeptides having significant sequence homology to DPPIV, nucleic acids coding therefor, cells which have been modified with such nucleic acid so as to express these proteins, antibodies to these proteins, screening methods for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins or of related proteins, and therapeutic agents discovered by such screening methods, as well as new therapeutic treatments, are all provided.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: January 2, 2007
    Assignee: Ferring BV
    Inventors: Steve Qi, Karen O. Akinsanya, Pierre J-M Riviere, Jean-Louis Junien
  • Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
    Patent number: 7153679
    Abstract: A novel arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII-activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: December 26, 2006
    Assignee: Aventis Behring GmbH
    Inventors: Stefan Kiechl, Johann Willeit, Christian Josef Wiedermann, Juergen Roemisch, Thomas Weimer, Annette Feussner, Hans-Arnold Stoehr, Volker Doersam, Wiegand Lang, Margret Becker, Claudia Nerlich, Gudrun Muth-Naumann, Bernd Knoblauch
  • Truncated aggrecanase molecules
    Patent number: 7150983
    Abstract: Truncated aggrecanase proteins and nucleotides sequences encoding them as well as processes for producing them are disclosed. Additionally, aggrecanases with amino acid mutations that lead to increased stability and expression levels in comparison with wild-type or native aggrecanases are also disclosed. Aggrecanases of the invention are especially useful for development of compositions for treatment of diseases such as osteoarthritis. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
    Type: Grant
    Filed: February 5, 2003
    Date of Patent: December 19, 2006
    Assignee: Wyeth
    Inventors: Katy E. Georgiadis, Tara K. Crawford, Kathleen N. Tomkinson, Lisa A. Collins-Racie, Christopher J. Corcoran, Bethany A. Freeman, Edward R. Lavallie
  • Nucleic acids encoding dipeptidyl peptidases
    Patent number: 7148338
    Abstract: The present invention provides nucleic acids that encodes a human dipeptidyl peptidase (DPP8), which shares structural and functional characteristics with dipeptidyl peptidase IV (DPPIV; CD26) and fibroblast activation protein (FAP). Vectors and cells comprising the nucleic acids are also disclosed.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: December 12, 2006
    Assignee: The University of Sydney
    Inventors: Catherine Anne Abbott, Mark Douglas Gorrell
  • Treatment of wounds
    Patent number: 7144721
    Abstract: An isolated protein, for use in treatment of wounds, is characterized in that it is secreted by the organism Lucilia sericata and it exhibits proteolytic activity against FITC-casein at a pH of 8.0 to 8.5. The protein exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC, and its proteolytic activity against FITC-casein and Tosyl-Gly-Pro-Arg-AMC is inhibited by the serine proteinase inhibitors PMSF and AMPSF. The protein is also bound by immobilized aminobenzamidine.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: December 5, 2006
    Assignee: The Secretary of the State of Defense, Defence Science and Technology Laboratory of Porton Down
    Inventor: David Idris Pritchard
  • Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof
    Patent number: 7138264
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: November 21, 2006
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey Strickland
  • Human PRSS11-Like S2 serine protease and uses thereof
    Patent number: 7132523
    Abstract: A novel human nucleic acid and polypeptide, termed PRSS11-L, are disclosed. PRSS11-L, which is observed in tissues throughout the body, can be used in methods of detection, gene therapy, and screening.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: November 7, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Andrew Lawrence Darrow, Jian-shen Qi, Cailin Chen, Patricia Andrade-Gordon
  • Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
    Patent number: 7125703
    Abstract: Provided herein are type II transmembrane serine protease 7 (MTSP7) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP7 are provided.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: October 24, 2006
    Assignee: Dendreon Corporation
    Inventors: Edwin L. Madison, Edgar O. Ong
  • Crosslinked elastin and process for producing the same
    Patent number: 7125960
    Abstract: A crosslinked elastin, a water-soluble crosslinking agent to be used for crosslinking, molded elastin articles, medical instruments and regeneration tissues using the crosslinked elastin, and a surgical therapy method and regeneration treatment wherein the medical instruments are employed. There is provided a biocompatible functional material having elasticity suitable for transplantation into the body without causing detachment of cell adhesion proteins.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: October 24, 2006
    Assignee: Chisso Corporation
    Inventor: Miyamoto Keiichi
  • Nucleic acid encoding a polypeptide promoting type II collagen formation and aggrecan production
    Patent number: 7125715
    Abstract: A novel polypeptide, a polynucleotide encoding this polypeptide, an expression vector comprising this polynucleotide, a cell transfected with the expression vector, and a pharmaceutical composition for promoting type II collagen production, a pharmaceutical composition for promoting aggrecan production, and a pharmaceutical composition for treating and/or preventing osteoarthritis comprising the above polypeptide as an active ingredient are disclosed. The polypeptide exhibits an activity of promoting type II collagen production and/or an activity of promoting aggrecan production.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: October 24, 2006
    Assignee: Astellas Pharma Inc.
    Inventor: Kunio Yasunaga
  • Modified ADAMTS4 molecules and method of use thereof
    Patent number: 7118902
    Abstract: The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: October 10, 2006
    Assignee: Wyeth
    Inventors: Christopher John Corcoran, Carl R. Flannery, Weilan Zeng, Lisa A. Racie, Thomas McDonagh, Bethany A. Freeman, Katy E. Georgiadis, Edward R. LaVallie
  • ?-secretase enzyme compositions and methods
    Patent number: 7115410
    Abstract: Disclosed are various forms of an active, isolated ?-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (?-APPwt and ?-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate ?-secretase. Inhibitors of ?-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 3, 2006
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John P. Anderson, Guriqbal Basi, Minh Tam Doan, Normand Frigon, Varghese John, Michael Power, Sukanto Sinha, Gwen Tatsuno, Jay Tung, Shuwen Wang, Lisa McConlogue
  • Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
    Patent number: 7112430
    Abstract: Provided herein are type II transmembrane serine protease 10 (MTSP10) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds that modulate the activity of an MTSP10 are provided.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: September 26, 2006
    Assignee: Dendreon Corporation
    Inventors: Edwin L. Madison, Jiunn-Chern Yeh
  • Masp-2, a complement-fixing enzyme, and uses for it
    Patent number: 7112414
    Abstract: The present invention relates to substantially pure mannan-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Furthermore, the present invention relates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositions comprising MASP-2 and/or MASP-2 fragments. In addition the present invention relates to inhibitors of MASP-2 and pharmaceutical compositions comparing such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: September 26, 2006
    Inventors: Jens Christian Jensenius, Steffen Thiel
  • ?-secretase enzyme compositions and methods
    Patent number: 7109017
    Abstract: Disclosed are various forms of an active, isolated ?-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (?-APPwt and ?-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate ?-secretase. Inhibitors of ?-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 19, 2006
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John P. Anderson, Guriqbal Basi, Minh Tam Doan, Normand Frigon, Varghese John, Michael Power, Sukanto Sinha, Gwen Tatsuno, Jay Tung, Shuwen Wang, Lisa McConlogue
  • Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
    Patent number: 7105333
    Abstract: Provided herein are type II transmembrane serine protease 9 (MTSP9) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP9 are provided.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: September 12, 2006
    Assignee: Deadreon Corporation
    Inventors: Edwin L. Madison, Edgar O. Ong
  • ICE/CED-3 like protease designated FMH-1
    Patent number: 7105331
    Abstract: Polynucleotides encoding novel proteases designated “FMH-1” are disclosed. Host cells transformed with such polynucleotides and methods for making FMH-1 proteases are also disclosed. The invention also provides FMH-1 proteases and antibodies that react with them, along with pharmaceutical compositions comprising FMH-1 proteases or polynucleotides encoding FMH-1 proteases. Methods for treating conditions associated with excessive or insufficient apoptosis by administering such pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: September 12, 2006
    Assignee: Genetics Institute, LLC
    Inventor: Michael R. Bowman
  • Modulators of regulatory proteins
    Patent number: 7101675
    Abstract: A modulator of regulatory cellular events occurring intracellularly which are mediated by regulatory proteins containing a ‘death domain’ motif is provided. The ‘death domain’ is a regulatory portion of the regulatory proteins, and the modulator is capable of interacting with one or more ‘death domain’ motifs contained in the regulatory proteins and affecting the regulatory action of one or more of the regulatory proteins. The modulator preferably is capable of interacting with ‘death domain’ motifs within p55-TNF-R, FAS/APO1-R, NGF-R, MORT-1, RIP, TRADD, or ankyrin. A method for producing the modulators is also provided. The modulators are useful for modulating functions mediated in cells by proteins containing the ‘death domain’.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: September 5, 2006
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Mark P Boldin, Eugene E Varfolomeev, Zeev Pancer, Igor Mett, Tanya M Goncharov
  • Aggrecanase
    Patent number: 7094590
    Abstract: A novel polypeptide, a polynucleotide encoding this polypeptide, an expression vector comprising this polynucleotide, a cell transfected with the expression vector, an antibody binding to the above polypeptide, a convenient screening method for obtaining an agent for treating joint diseases, and a process for manufacturing a pharmaceutical composition for treating joint diseases are disclosed. The polypeptide is a novel aggrecanase causative of joint diseases (particularly an OA disease).
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: August 22, 2006
    Assignee: Astellas Pharma Inc.
    Inventors: Noboru Yamajii, Kouichi Nishimura, Kunitake Abe
  • Human aggrecanase and nucleic acid compositions encoding the same
    Patent number: 7094591
    Abstract: Human aggrecanase and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting aggrecanase activity in a host and methods of treating disease conditions associated with aggrecanase activity, e.g. rheumatoid arthritis, osteo-arthritis, infectious arthritis, gouty arthritis, psoriatic arthritis, spondolysis, sports injury, joint trauma, pulmonary disease, fibrosis, and the like.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: August 22, 2006
    Assignee: Syntex (U.S.A.) LLC
    Inventors: John David Allard, Renu Anand Heller, Paul Klonowski, Harold Edgar Van Wart
  • Human enzymes of the metalloprotease family
    Patent number: 7083965
    Abstract: This invention relates to newly identified polypeptides which have zinc metalloprotease activities and are referred to as IGS5, and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be stimulators and/or inhibitors which are useful in therapy, and to production of such polypeptides and polynucleotides.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: August 1, 2006
    Assignee: Solvay Pharmaceuticals B.V.
    Inventors: Willy Deleersnijder, Rico Wiegers, Michael Weske
  • Methods for screening compounds that bind human COE-2
    Patent number: 7081344
    Abstract: The invention provides isolated nucleic acid molecules, designated COE-2 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing COE-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a COE-2 gene has been introduced or disrupted. The invention still further provides isolated COE-2 proteins, fusion proteins, antigenic peptides and anti-COE-2 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: July 25, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Inmaculada Silos-Santiago
  • Aggrecanase molecules
    Patent number: 7078217
    Abstract: Novel aggrecanase proteins and the nucleotide sequences encoding them as well as processes for producing them are disclosed. Methods of identifying and developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: July 18, 2006
    Assignee: Wyeth
    Inventors: Christopher J. Corcoran, Michael J. Agostino, Edward R. LaVallie, Carl R. Flannery, Lisa A. Collins-Racie
  • Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
    Patent number: 7074401
    Abstract: It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys300?His), perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: July 11, 2006
    Assignee: Thrombolytic Science, Inc.
    Inventors: Victor Gurewich, John N. Williams, Jian-Ning Liu, Paolo Sarmientos, Massimiliano Pagani
  • Matrix metalloproteinase polypeptide
    Patent number: 7070976
    Abstract: The present invention provides genes encoding novel matrix metalloproteinases termed MMP; constructs and recombinant host cells incorporating the genes; the MMP polypeptides encoded by the genes; antibodies to the MMP polypeptides; and methods of making and using all of the foregoing.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: July 4, 2006
    Assignee: Pfizer Inc.
    Inventors: Timothy Wood, Jonas Ekblom, Erik Holmgren, Mats Kihlén
  • Human serine protease D-G polypeptide
    Patent number: 7070977
    Abstract: Polypeptides corresponding to a novel S1 serine protease family member, termed protease D-G, and nucleic acids encoding them are described. The materials may be used, for example, in screening assays to identify protease D-G modulators and in methods for diagnosing or treating conditions associated with aberrant protease D-G activity.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: July 4, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Andrew L. Darrow, Jenson (Jian-Shen) Qi, Patricia Andrade-Gordon
  • Protein hydrolysates produced with the use of cod proteases
    Patent number: 7070953
    Abstract: The invention relates to a method for enzymatically obtaining protein hydrolysates for human consumption, animal feed and cosmetics. The process involves the use of a proteolytic composition derived from fish, such as Cod (Gadus morhua), to obtain hydrolysates which have a non-bitter taste and retain the flavor and aroma of the protein-containing material which is hydrolyzed: e.g. when hydrolyzing protein-containing material from marine organisms or parts thereof, such as fish, shrimp, lobster or other seafood according to the invention, a protein hydrolysate is produced that has a characteristic natural flavor of the organism Also provided are food products comprising the hydrolysates of the invention, such as soup, sauce, cheese, HVP, meat extract and flavoring agent, broth, paté, mousse, frying dough, orly dough, and pastries.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: July 4, 2006
    Assignee: Nordur EHF
    Inventors: Jon Bragi Bjarnason, Bergur Benediktsson
  • ?-secretase enzyme compositions and methods
    Patent number: 7067271
    Abstract: Disclosed are various forms of an active, isolated ?-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (?-APPwt and ?-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate ?-secretase. Inhibitors of ?-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: June 27, 2006
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John P. Anderson, Guriqbal Basi, Minh Tam Doan, Normand Frigon, Varghese John, Michael Power, Sukanto Sinha, Gwen Tatsuno, Jay Tung, Shuwen Wang, Lisa McConlogue
  • MASP-2, a complement-fixing enzyme, and uses for it
    Patent number: 7060267
    Abstract: The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.
    Type: Grant
    Filed: January 11, 2005
    Date of Patent: June 13, 2006
    Inventors: Jens Chr. Jensenius, Steffen Thiel
  • Crystal structure of cysteine protease
    Patent number: 7052851
    Abstract: The present invention relates to the death protease CPP32 in crystallized form and a method for the preparation thereof. The invention further provides a three-dimensional model of CPP32 and improved means for the design of CPP32 modulators.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: May 30, 2006
    Assignee: Novartis International AG
    Inventors: Peer Mittl, Stefania Di Marco, Markus Grütter
  • Human serine protease
    Patent number: 7049126
    Abstract: Members of the serine protease family play a role in carefully controlled processes, such as blood coagulation, fibrinolysis, complement activation, fertilization, and hormone production. These enzymes are also used in a variety of diagnostic, therapeutic, and industrial contexts. Ztryp3 is a new member of the serine protease family.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: May 23, 2006
    Assignee: ZymoGenetics, Inc.
    Inventor: Darrell C. Conklin
  • Human protease molecules
    Patent number: 7045333
    Abstract: The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: May 16, 2006
    Assignee: Incyte Corporation
    Inventors: Olga Bandman, Jennifer L. Hillman, Henry Yue, Karl J. Guegler, Neil C. Corley, Y. Tom Tang, Purvi Shah
  • Storage-stable, liquid fibrinogen formulation
    Patent number: 7045601
    Abstract: The present invention relates to a novel storage-stable formulation for fibrinogen in liquid or viscous liquid form comprising divalent metal ions. The fibrinogen formulation may comprise other conventional formulation ingredients and particularly preferably comprises a complexing agent. The invention further relates to the production and use of the fibrinogen formulation of the invention.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: May 16, 2006
    Assignee: ZLB BEHRING GmbH
    Inventors: Hubert Metzner, Uwe Liebing, Gerhardt Kumpe, Stefan Schulte, Volker Gawantka, Karlheinz Enssle